1. Home
  2. PRLD vs NEUE Comparison

PRLD vs NEUE Comparison

Compare PRLD & NEUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • NEUE
  • Stock Information
  • Founded
  • PRLD 2016
  • NEUE 2015
  • Country
  • PRLD United States
  • NEUE United States
  • Employees
  • PRLD N/A
  • NEUE N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • NEUE
  • Sector
  • PRLD Health Care
  • NEUE
  • Exchange
  • PRLD Nasdaq
  • NEUE NYSE
  • Market Cap
  • PRLD 73.7M
  • NEUE 60.7M
  • IPO Year
  • PRLD 2020
  • NEUE 2021
  • Fundamental
  • Price
  • PRLD $0.81
  • NEUE $6.40
  • Analyst Decision
  • PRLD Strong Buy
  • NEUE Hold
  • Analyst Count
  • PRLD 2
  • NEUE 1
  • Target Price
  • PRLD $4.50
  • NEUE $7.00
  • AVG Volume (30 Days)
  • PRLD 279.1K
  • NEUE 19.3K
  • Earning Date
  • PRLD 05-06-2025
  • NEUE 05-07-2025
  • Dividend Yield
  • PRLD N/A
  • NEUE N/A
  • EPS Growth
  • PRLD N/A
  • NEUE N/A
  • EPS
  • PRLD N/A
  • NEUE N/A
  • Revenue
  • PRLD $7,000,000.00
  • NEUE $936,657,000.00
  • Revenue This Year
  • PRLD N/A
  • NEUE $33.99
  • Revenue Next Year
  • PRLD N/A
  • NEUE $5.90
  • P/E Ratio
  • PRLD N/A
  • NEUE N/A
  • Revenue Growth
  • PRLD N/A
  • NEUE N/A
  • 52 Week Low
  • PRLD $0.61
  • NEUE $3.79
  • 52 Week High
  • PRLD $6.80
  • NEUE $7.66
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 57.52
  • NEUE 48.94
  • Support Level
  • PRLD $0.71
  • NEUE $6.03
  • Resistance Level
  • PRLD $0.72
  • NEUE $6.84
  • Average True Range (ATR)
  • PRLD 0.08
  • NEUE 0.34
  • MACD
  • PRLD 0.02
  • NEUE 0.03
  • Stochastic Oscillator
  • PRLD 76.92
  • NEUE 48.86

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About NEUE NEUEHEALTH INC

NeueHealth Inc is a value driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. It also enables independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally.

Share on Social Networks: